Form 4: Bionano Genomics Principal Accounting Officer Acquires Stock Options
SEC Form 4 Filing
Mark Adamchak, Principal Accounting Officer of Bionano Genomics, acquired stock options for 3,029 shares of common stock on March 14, 2025.
Summary
- On March 14, 2025, Mark Adamchak, the Principal Accounting Officer of Bionano Genomics, acquired stock options.
- These options grant him the right to buy 3,029 shares of Bionano Genomics common stock at an exercise price of $3.47 per share.
- The options vest 100% on the one-year anniversary of the grant date and expire on March 13, 2035.
- Following this transaction, Adamchak directly owns options for 3,029 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports the grant of stock options, a common practice in executive compensation.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's future prospects.
Stakeholder Impact
- The granting of stock options to a key executive could potentially align management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of stock option grant and transaction. |
| 03/13/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.